After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis (PsA). | After ...
New data show bimekizumab is the first approved biologic to achieve superior outcomes in psoriatic arthritis vs an IL-23 ...
Please provide your email address to receive an email when new articles are posted on . Izokibep achieved ACR50 response at week 16 in a phase 2b/3 PsA trial and showed continued benefit in a ...
AbbVie (ABBV) stock is in focus as UCB (UCBJY) says its Bimzelx beat Skyrizi in a head-to-head psoriatic arthritis trial. Read more here.
LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...
ATLANTA, March 11, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX ® (bimekizumab) versus SKYRIZI ® ...
Findings showed 31.7% of patients receiving ixekizumab and tirzepatide achieved both ACR50 and at least 10% weight loss vs 0.8% on ixekizumab monotherapy. Topline data were announced from a phase 3b ...
UCB has announced positive topline results from its BE BOLD trial, the first head‑to‑head study in active psoriatic arthritis to demonstrate superiority of one licensed biologic therapy over an IL‑23 ...
MILAN -- A novel oral agent that blocks two different kinase enzymes was possibly more effective against rheumatoid arthritis (RA) than the currently approved drug tofacitinib (Xeljanz) in a ...
A decision-analytic model could save more than $7 million in overall ineffective health care costs per 1000 patients by predicting which patients with rheumatoid arthritis (RA) will have an inadequate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results